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ABSTRACT
Objectives: To estimate the lifetime risk, prevalence, incidence, and mortality of the principal clin-
ical syndromes associated with frontotemporal lobar degeneration (FTLD) using revised diagnos-
tic criteria and including intermediate clinical phenotypes.
Methods: Multisource referral over 2 years to identify all diagnosed or suspected cases of fron-
totemporal dementia (FTD), progressive supranuclear palsy (PSP), or corticobasal syndrome
(CBS) in 2 UK counties (population 1.69 million). Diagnostic confirmation used current consensus
diagnostic criteria after interview and reexamination. Results were adjusted to the 2013 Euro-
pean standard population.
Results: The prevalence of FTD, PSP, and CBS was 10.8/100,000. The incidence and mortality
were very similar, at 1.61/100,000 and 1.56/100,000 person-years, respectively. The esti-
mated lifetime risk is 1 in 742. Survival following diagnosis varied widely: from PSP 2.9 years
to semantic variant FTD 9.1 years. Age-adjusted prevalence peaked between 65 and 69 years
at 42.6/100,000: the age-adjusted prevalence for persons older than 65 years is double the
prevalence for those between 40 and 64 years. Fifteen percent of those screened had a relevant
genetic mutation.
Conclusions: Key features of this study include the revised diagnostic criteria with improved spec-
ificity and sensitivity, an unrestricted age range, and simultaneous assessment of multiple FTLD
syndromes. The prevalence of FTD, PSP, and CBS increases beyond 65 years, with frequent
genetic causes. The time from onset to diagnosis and from diagnosis to death varies widely
among syndromes, emphasizing the challenge and importance of accurate and timely diagnosis.
A high index of suspicion for FTLD syndromes is required by clinicians, even for older patients.
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GLOSSARY
bvFTD 5 behavioral variant frontotemporal dementia; CBS 5 corticobasal syndrome; ESP2013 5 European Standard
Population 2013; FTD 5 frontotemporal dementia; FTLD 5 frontotemporal lobar degeneration; MND 5 motor neuron dis-
ease; nfvPPA5 nonfluent agrammatic variant primary progressive aphasia; PiPPIN5 Pick’s Disease and Progressive Supra-
nuclear Palsy: Prevalence and Incidence; PPA 5 primary progressive aphasia; PSP 5 progressive supranuclear palsy;
svPPA 5 semantic variant primary progressive aphasia.
Frontotemporal lobar degeneration (FTLD) causes diverse clinical syndromes including behav-
ioral variant frontotemporal dementia (bvFTD), with or without motor neuron disease (MND);
primary progressive aphasias (PPAs) (semantic variant [svPPA], nonfluent agrammatic
variant [nfvPPA], and logopenic variant); progressive supranuclear palsy (PSP) (Steele-Richardson-
Olszewski syndrome); and the corticobasal syndrome (CBS). These syndromes are common
causes of young-onset dementia,1,2 but there are potential limitations to previous estimates of
prevalence and incidence. First, the diagnostic criteria have been revised significantly in recent
years3–6 with changes in specificity and sensitivity.4 For example, many patients who met former
criteria for bvFTD had normal imaging and minimal progression.7 These “phenocopy” cases are
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now excluded. Second, intermediate pheno-
types of uncertain nosologic status lay outside
former diagnostic categories, e.g., the overlap
between PSP and CBS.5,8 Furthermore, a
patient’s syndrome may evolve to another.9,10
As a consequence, the sum of prevalence esti-
mates of single disorders might not accurately
reflect their overall prevalence. Third, previous
studies used widely varying methods, often
with cumulative rather than point prevalence
and different age ranges. This hinders compar-
isons across studies.2
To address these limitations, we prospec-
tively recruited all cases over 2 years from 2
UK counties (population 1.69 million) using
multisource identification from primary, sec-
ondary, and tertiary care, self-referral, and rel-
evant patient charities. We reassessed them
and applied the new diagnostic criteria with
the goal of achieving a more accurate estimate
of the prevalence and incidence of the major
FTLD-associated syndromes.
METHODS The PiPPIN (Pick’s Disease and Progressive
Supranuclear Palsy: Prevalence and Incidence) Study was
approved by Cambridge’s research ethics committee. The catch-
ment area included Cambridgeshire and Norfolk in the East of
England. Their combined population was 1.69 million according
to the 2013 UK Office for National Statistics midyear estimate,11
covering urban and rural populations with a full socioeconomic
range. The area subdivides into 13 local authority districts with
populations of 85,398 to 188,373.11 We sought identification of
all cases with a reference diagnosis between January 1, 2013, and
December 31, 2014.
Multiple sources of case identification were used, including
regional specialist clinics for frontotemporal dementia (FTD), other
disorders of movement and cognition, and early dementia. These
clinics receive referrals from primary, secondary, and tertiary care
services for dementia, Parkinson disease and related disorders,
MND, adult neurology, medicine for the elderly, adult- and old-
age psychiatry; memory clinics; and regional community-based spe-
cialist nurses for Parkinson disease, young-onset dementia, and
dementia. Referral sources were contacted in person, by letter,
and by e-mail before and during the study. Direct referrals were
accepted from clinical research networks including the National
Institute for Health Research Clinical Research Network Demen-
tias and Neurodegeneration Speciality and theWest Anglia Clinical
Research Network. We included patients notified to us by self-
referral, local newspaper advertisements for the PiPPIN Study,
and letters of invitation to members of local and national charities
(the UK FTD support group and PSP Association).
To identify people who were no longer under review, we
searched our clinic databases for cases with a relevant diagnosis
since 2003. We confirmed survival and address by clinical re-
cords. To maintain awareness of PiPPIN and promote case noti-
fication of patients, the study team made frequent presentations
to relevant national and regional conferences, meetings, research
groups, support groups, and charities.
Referring services were required to record consent for case
notification. Patients assessed within the study (including notes
review) provided additional written informed consent. Patients
who lacked mental capacity to consent to research participation
under UK law were eligible for inclusion, and we adopted the
“consultee process” as set out by the Mental Capacity Act (2005).
For patients who were willing to be reviewed by the study
team, a neurologist applied the revised diagnostic criteria based
on clinical interview, physical examination, and relevant tests
including brain imaging. For cases that were unable or unwilling
to be assessed in person, we accessed existing medical records.
Participants were invited to a detailed clinical assessment
either at the study center or their home, residential home, or nurs-
ing home. This included (1) semistructured interviews of patient
and carer for clinical history and demographic data; (2) structured
patient and carer assessment of symptoms and severity; (3) struc-
tured assessment of speech, language, and cognition; (4) neuro-
logic examination; and (5) MRI of the brain. Results of
investigations during clinical diagnosis were accessed from the pa-
tient’s medical records including neuropsychological assessments,
neuroimaging, and genetic testing. Inability to travel, or residence
in a care home, did not preclude participation in any aspect of the
study, except MRI. For patients unable or unwilling to undergo
parts of the assessment, a pragmatic approach was taken priori-
tizing diagnostic accuracy. Forty-six patients consented to addi-
tional genetic screening for 17 known genetic causes of FTLD
and non-FTLD dementia.12
The diagnostic criteria for bvFTD,4 PPA syndromes,3 PSP,6
and CBS5 were applied. We present the dominant syndrome or
phenotype using these criteria. To be inclusive of all cases within
the spectrum of FTLD-associated disorders, special consideration
is required when applying the criteria to cases that lie at a bound-
ary between 2 categories, or who present with an overlap of clin-
ical features. For example, a hypothetical patient may present
with an atypical svPPA, with their principal complaint being
typical of the language disorder but with predominant behavioral
disturbance under observation. Such a patient may lie outside of
the svPPA criteria3 but also not meet bvFTD criteria in view of
the level of semantic deficits and absence of other bvFTD fea-
tures. Excluding such a patient would underestimate prevalence
of FTLD-associated syndromes. Conversely, another patient
might meet criteria for CBS-NAV5 but also nfvPPA.3 They
should clearly only be counted once when estimating the aggre-
gated prevalence of FTLD-associated syndromes. Where there
was diagnostic ambiguity, a second neurologist reviewed the case
and a consensus was reached, based on the principal syndromic
features.
Age at onset was the age of the patient when the earliest symp-
tom of dementia was noted by the patient or carers. Age at diag-
nosis was defined as the age at which a neurodegenerative disorder
was first considered as a likely cause of the patient’s symptoms by
a specialist. We also recorded the date at which a specific FTLD-
associated diagnosis was first considered. Prevalent cases were
defined as those alive on January 1, 2014. Incident cases were
defined as those first diagnosed during the study period. Survival
in this report refers to the duration from age at onset to death, of
patients who died during the study period.
Prevalence rates were calculated as the number of prevalent
cases divided by the population of the catchment area using the
UK Census 2013 midyear estimates.11 To identify regional differ-
ences in case identification, prevalence rates were also calculated
for each local authority. Incidence was calculated by dividing
the total number of incident cases by the total number of
person-years for the catchment area population over 2 years.
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Standardized rates were calculated using the Revised European
Standard Population 2013 (ESP2013). Age- and sex-standardized
lifetime risk was calculated using the current probability
method.13,14 First, age-specific prevalence, incidence, and mortal-
ity rates were standardized to the ESP2013. Using incidence and
death rates from our data, we calculated the risk of developing
disease and of dying of it within specific age ranges. We then
adjusted for the risk of dying of other causes (using census all-
cause mortality) to give age-specific current probability of devel-
oping disease. The sum of current probabilities for all age groups
gives the lifetime risk, i.e., the probability of an individual devel-
oping FTLD during their life adjusted for the risk of dying of
other causes first.15
RESULTS Two hundred thirty-four patients were
assessed; 176 were referred via clinical services, 52
from clinical and research database searches. One
hundred ninety-seven patients were reviewed in
person by the study team (84.2%). Two hundred
four cases of FTLD-associated syndromes were
identified in the catchment area over the study
period; 30 patients were rejected after review. Of
the 204 patients, 167 patients (81.7%) were seen
by the study team. Clinical records of consultant
neurologist or psychiatrist assessments were available
in all of the remaining cases. Detailed information
sufficient to apply the diagnostic criteria in full was
available for 200 cases (98.0%). The patients with
limited information included 2 with PSP and 2
with FTD-MND. Table 1 shows the mean age,
clinical features, and years since symptom onset at
the time of assessment. The bvFTD group includes
8 cases with clinical features of MND (19%, table 1).
One hundred eighty-two patients were alive on
January 1, 2014 (89 men, 93 women), giving a crude
prevalence of 10.77/100,000. The European-
standardized prevalence (95% confidence intervals)
was as follows: men 10.93/100,000 (8.66–13.20),
women 10.76/100,000 (8.57–12.95), and sex-
standardized 10.84 (9.27–12.42).
Figure 1 shows prevalence rates by local authority
boundaries, age of diagnosis, and syndrome. Preva-
lence rates by local authority ranged from 4.09 to
21.7/100,000 but were not driven by proximity to
the major cities or study center.
The youngest age at onset was 41 years. The
ESP2013 age- and sex-standardized prevalence for
the age range 40–64 was 13.05 (10.01–16.08) and
33.20 (27.02–39.37) for those older than 65 years.
One-way analysis of variance of age at diagnosis
indicated a significant effect of diagnosis (F5,181 5
4.89, p , 0.001). Post hoc comparisons (unequal
variances, Bonferroni correction) confirmed signifi-
cant differences between PSP and bvFTD (p ,
0.005), other PPA and bvFTD (p , 0.01), and
PSP vs svPPA (p , 0.05).
Age at onset and neurodegenerative and FTLD-
associated syndrome diagnoses were available for
193 patients (95%). Missing data were substituted
by the mean within syndrome. Fifty-four patients
(23 men, 31 women) died during the assessment
period, giving an age-adjusted all-cause mortality
from FTLD of 1.57 (1.15–1.99) per 100,000
person-years. By April 31, 2015, 6 additional patients
Table 1 Clinical features at the time of detailed clinical assessment for 200 of 204 cases identified during the PiPPIN Study
All bvFTD PSP CBS nfvPPA svPPA PPA
Total cases 200 42 48 48 28 23 11
M/F 93/107 19/23 29/19 17/31 11/17 12/11 5/6
Mean age at assessment, y (SD) 69.4 (8.7) 63.7 (7.9) 72.6 (7.8) 70.8 (8.5) 70.6 (9.8) 66.7 (6.7) 72.6 (7.8)
Mean years from onset to assessment (SD) 4.3 (2.9) 4.4 (3.0) 4.7 (3.5) 4.4 (2.7) 3.7 (2.5) 4.4 (2.7) 4.2 (2.3)
Behavioral changes, n (%) 158 (79) 42 (100.0) 40 (83.3) 36 (75.0) 13 (46.4) 22 (95.7) 5 (45.5)
Language impairment, n (%) 138 (69.0) 31 (73.8) 13 (27.1) 32 (66.7) 28 (100.0) 23 (100.0) 11 (100.0)
Akinesia, n (%) 110 (55.0) 27 (64.3) 43 (89.6) 30 (62.5) 5 (17.9) 3 (13.0) 2 (18.2)
Rigidity (%) 85 (42.5) 9 (21.4) 41 (85.4) 33 (68.8) 1 (3.6) 0 (0.0) 1 (9.1)
Dystonia, n (%) 58 (29.0) 4 (9.5) 28 (58.3) 26 (54.2) 0 (0.0) 0 (0.0) 0 (0.0)
Apraxia, n (%) 108 (54.0) 12 (28.6) 25 (52.1) 45 (93.8) 16 (57.1) 2 (8.7) 8 (72.7)
Supranuclear gaze paresis, n (%) 76 (38.0) 3 (7.1) 47 (97.9) 22 (45.8) 2 (7.1) 0 (0.0) 2 (18.2)
Postural instability/falls, n (%) 89 (44.5) 7 (16.7) 47 (97.9) 32 (66.7) 2 (7.1) 0 (0.0) 1 (9.1)
Features of motor neuron disease, n (%) 9 (4.5) 8 (19.0) 0 (0.0) 1 (2.1) 0 (0.0) 0 (0.0) 0 (0.0)
Abbreviations: bvFTD 5 behavioral variant frontotemporal dementia; CBS 5 corticobasal syndrome; nfvPPA 5 nonfluent agrammatic variant primary
progressive aphasia; PiPPIN 5 Pick’s Disease and Progressive Supranuclear Palsy: Prevalence and Incidence; PPA (other) 5 other forms of primary pro-
gressive aphasia (including logopenic and unclassifiable variant); PSP 5 progressive supranuclear palsy; svPPA 5 semantic variant primary progressive
aphasia.
Assignment to each syndrome was made on the basis of the primary aspect(s) of the disorder at presentation; additional features may develop over time
and are indicated at the time of PiPPIN participation to indicate the deficits in prevalent cases, not limited to incident cases.
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had died. Figure 2 shows the length of symptomatic
disease split by time before a neurodegenerative diag-
nosis, FTLD diagnosis, and death for the 60 deceased
patients.
Fifty-three incident cases were identified (24 men,
29 women), giving crude and standardized incidence
rates of 1.57 and 1.61 (1.14–1.99) per 100,000
person-years, respectively. Figure 3 shows the crude
incidence rates by age at onset and neurodegenerative
diagnosis across all syndromes by age group. The life-
time risk (standardized for age and sex) was 1 in 742.
Forty-six patients (23%) underwent genetic
screening (11 svPPA, 11 nfvPPA, 4 PPA [other], 17
bvFTD, 3 CBS, 1 PSP). Seven patients (15%) carried
a relevant mutation (table e-1 on theNeurology®Web
site at Neurology.org).
DISCUSSION We combined point-prevalence
methods with an unrestricted age range and the
2011/2013 revised diagnostic criteria for major
FTLD-associated clinical syndromes. We did not
restrict our analysis to young-onset cases. The
prevalence of all disorders taken together was
10.84/100,000 with similar prevalence of bvFTD,
PSP and CBS, and PPA (all subtypes). The
estimated lifetime risk of one of these disorders is
1 in 742.
The overall prevalence estimate is in line with pre-
vious studies, including those with restricted age
ranges1,16–20 and/or selected syndromes.2,17,19–24 The
data indicate that overall prevalence increases beyond
age 65: the prevalence among those older than 65
years was more than double that of those aged
Figure 1 Prevalence of FTLD-associated syndromes
(A) The local authorities in England, with enlargement of the PiPPIN catchment area in the East of England. The asterisks mark the 2 cities (Norfolk and Cam-
bridge) within the catchment area. The color code indicates crude prevalence rates of FTLD-associated clinical syndromes for each local authority. (B) Crude
prevalence rates for the major FTLD-associated syndromes by age and (C) by age and syndrome. (D) Total number of prevalence cases for each syndrome.
bvFTD 5 behavioral variant frontotemporal dementia; CBS 5 corticobasal syndrome; FTLD 5 frontotemporal lobar degeneration; nfvPPA 5 nonfluent
agrammatic variant primary progressive aphasia; other PPA 5 other primary progressive aphasia; PiPPIN 5 Pick’s Disease and Progressive Supranuclear
Palsy: Prevalence and Incidence; PSP 5 progressive supranuclear palsy; svPPA 5 semantic variant primary progressive aphasia. (A) Contains National
Statistics data © Crown copyright and database right [2013]; contains Ordnance Survey data © Crown copyright and database right [2013].
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40 to 64 years. The bvFTD had the youngest peak age
at diagnosis (peak 60–64 years, median age at diagnosis
63), with later peak ages at diagnosis for PSP (70–74
years) and CBS and nfvPPA (75–79 years).
Many previous studies have been restricted to
individual syndromes. For example, when estimating
the prevalence of FTD, some studies included
PPA1,19–21,25–27 while others restricted their estimates
to bvFTD,16–18 limiting ability to directly compare
between them. For FTD (not including PSP/cortico-
basal degeneration), the UK prevalence was previ-
ously reported as 15.1/100,000 (8.4–27.0) in the
45 to 64 age group1 with an incidence of
1.3/100,000 (2.0–5.7) person-years.25 The diagnostic
criteria used in these studies may have included non-
progressive “phenocopies.”7 We identified (and
excluded) 2 such cases during screening. The identi-
fication of pathologic expansions of C9ORF7228 has
renewed interest in these cases, but both cases were
negative for C9ORF72. However, we identified (and
included) one slowly progressive case who at first pre-
sentation had normal brain imaging and would not
initially have met current criteria for probable
bvFTD. He subsequently developed generalized
atrophy and was identified as carrying a pathologic
expansion of C9ORF72.
We included PSP and CBS in the study, as syn-
dromes associated with FTLD. Although they often
present with a movement disorder, they may have
prominent cognitive and behavioral features in a third
of cases,29 overlapping with other FTLD-associated
syndromes,8–10,30 especially nfvFTD and bvFTD
(see table 1). The overlap tends to increase with
time.9,10 Epidemiologic studies of PSP have mainly
used case notification to specialist centers or reviewed
cases of parkinsonism. With reexamination of
suspected cases, prevalence was estimated to be
0.15/100,000 and incidence 0.3–0.4/100,000.22 A
second study23 used a computerized search of terms
relating to parkinsonism and clinical reevaluation to
estimate prevalence of 6.4/100,000 (2.3–10.6). A
third study24 used both methods to estimate preva-
lences of 0.3 and 5.0/100,000.
There are limited and divergent data on the epide-
miology of CBS. For example, one case was identified
from 534 incident cases of parkinsonism31 while none
were identified among an urban population of
121,628.23 A limiting factor for studies of CBS is
diagnostic uncertainty. Fewer than two-thirds of cases
with clinical CBS have pathologic features of cortico-
basal degeneration and vice versa.32 We used the
revised diagnostic criteria,5 which aim to improve sen-
sitivity, and did not restrict our cohort to movement
disorder clinics or incident cases of parkinsonism. By
selecting cases based on both motor and nonmotor
aspects of their illness, we identified substantially
more cases than previous studies.23,31
Despite revised criteria, diagnostic difficulties
remain that will affect epidemiologic research, espe-
cially for studies that focus on one syndrome rather
than the broader spectrum of FTLD-associated syn-
dromes. Furthermore, the nosology and nomencla-
ture of FTLD syndromes have changed many
times9 and may continue to evolve. Although categor-
ical decisions are required for diagnosis, the bound-
aries between FTLD-associated syndromes become
indistinct with time. For example, 95% of patients
with svPPA had developed behavioral changes, and
most patients with bvFTD subsequently developed
language impairment. Language impairments were
common in CBS (66.7%), behavioral changes in
PSP (83.3%), and motor features commonly emerged
in all FTD subtypes. Our inclusive approach does not
undermine the importance of diagnostic classification
but emphasizes the heterogeneous and progressive
nature of these disorders. The data demonstrate the
need to account for transitional and intermediate
clinical phenotypes in epidemiologic estimates and
in consideration of clinical trials.
Within the spectrum of FTLD, the subtypes are
each associated with more than one clinical syn-
drome. We cannot speak to the pathology of our cases
except in the genetic cases and refer the reader to pub-
lished studies of clinicopathologic correlations.32–37
We sought to identify and examine all cases where
FTLD was considered, but cases in which it was not
suspected will have been missed. The majority of
cases were known to tertiary clinical services; how-
ever, relying solely on this route would have missed
Figure 2 Survival with FTLD-associated syndromes
Mean duration from the onset of symptoms to the diagnosis of a neurodegenerative disorder
(blue); to the specific diagnosis of an FTLD-associated syndrome (gold); and to death (green)
for all 60 patients who have died since the start of the PiPPIN Study. Inserted figures indi-
cate themean duration of each phase for each syndrome and all patients combined. bvFTD5
behavioral variant frontotemporal dementia; CBS 5 corticobasal syndrome; FTLD 5 fronto-
temporal lobar degeneration; nfvPPA 5 nonfluent agrammatic variant primary progressive
aphasia; PSP5 progressive supranuclear palsy; svPPA5 semantic variant primary progress-
ive aphasia.
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nearly a quarter of cases. Sources of referral were not
independent, and UK data protection and confiden-
tiality laws prevent identification of any cases that
were not referred and this limits analysis of potential
referral bias. From discussions with referrers in
regional meetings, we are aware of only one patient
who initially refused to be included in the study, sug-
gesting good ascertainment of known cases of FTLD.
However, in a community-based study of aging,38 3
of 456 postmortem cases had evidence of PSP pathol-
ogy. All 3 had symptoms that could be retrospectively
attributed to PSP but none were diagnosed during life
(Brayne, unpublished data, 2014). Hence, the true
prevalence and incidence of FTLD pathology may
be substantially higher than the prevalence and inci-
dence of diagnosed cases. Similarly, the decrease in
prevalence among older age groups may be
attributable to reduced index of suspicion for
FTLD syndromes. Rising rates of non-FTLD neu-
rodegeneration (e.g., Alzheimer disease) may over-
shadow less common conditions such as FTLD or
(in the case of dual pathology) alter the clinical
phenotype so that an FTLD diagnosis is not
recognized.
We confirmed all identified cases were alive and
resident within the catchment area during the study.
By liaising with national charities and clinical services
beyond the PiPPIN catchment area, we aimed to
identify any cases not previously known to our serv-
ices who migrated into the area.
We did not include cases of MND without FTD
although we are aware that some MND cases will
have mild cognitive impairments. MND has a life-
time risk of approximately 1 in 400.15 Including
MND cases with only mild cognitive impairment
would overestimate the prevalence of symptomatic
FTD syndromes. Eight (19%) of our bvFTD cases
had clinical features of MND. The case of CBS with
MND features is notable, possibly reflecting the range
of pathologic causes of CBS.32
It should also be noted that screening for genetic
mutations was not performed randomly. The screened
cohort was dominated by nonmotor syndromes (PPA
or bvFTD). Among this subgroup, the frequency of
mutations identified is similar to previous studies since
the discovery of C9ORF72.39 The finding of relevant
mutations in 2 patients with typically sporadic syn-
dromes (svPPA and CBS) illustrates the challenges to
clinical segregation of FTLD. Three of 7 patients car-
rying mutations were diagnosed before the age of 60. It
is conceivable that the presence of genetic mutations or
additional features (such as MND) may influence fac-
tors such as age at onset or survival. However, the small
numbers reported here preclude sufficiently powered
comparisons.
The incidence of 1.61/100,000 person-years is
similar to the mortality (1.56/100,000 person-
years). Assuming constant prevalence, mortality
serves as an additional surrogate estimate of inci-
dence, suggesting that the study achieved “steady
state” of referrals of incident cases. We report stan-
dardized prevalence and incidence estimates across all
ages rather than report peak rates in the highest risk
groups to allow comparison with other studies and
other conditions. Time from onset to diagnosis and
subsequent survival varied between syndromes. This
may reflect different indices of suspicion for an under-
lying neurologic condition for different presentations
or common misdiagnosis as a primary psychiatric
disorder.
We have shown that the revised diagnostic criteria
for FTLD-associated syndromes can be applied
jointly in a multisource epidemiologic study without
Figure 3 Incidence of FTLD-associated syndromes
(A) Incidence of FTLD-associated syndromes by age at onset (green bars) and by age at diagno-
sis (blue bars). (B) Distribution of incident cases by clinical syndrome (n 5 53). bvFTD 5 behav-
ioral variant frontotemporal dementia; CBS 5 corticobasal syndrome; FTLD 5 frontotemporal
lobar degeneration; nfvPPA5 nonfluent agrammatic variant primary progressive aphasia; other
PPA 5 other primary progressive aphasia logopenic variant (n 5 2) and unclassifiable (n 5 2);
PSP 5 progressive supranuclear palsy; svPPA 5 semantic variant primary progressive aphasia.
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restriction to young-onset cases or single syndromes.
The resulting prevalence, incidence, and survival data
will allow better generalization of results from clinical,
genetic, and pathologic studies of FTLD. Further-
more, they enable unbiased interventional studies
with reference to the whole population of affected pa-
tients including sporadic cases and those older than
65 years.
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